US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Alex Therapeutics has signed an exclusive agreement with Navamedic for the development of a Companion App to aid in the treatment of Parkinson’s Disease

Stockholm Sweden, September 12, 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, has partnered with Alex Therapeutics, a digital health provider of disease and drug companion apps, to aid in Parkinson’s treatment management. The app will be developed by Alex Therapeutics to support patients on Flexilev®, a prescription treatment for Parkinson’s disease.   The new companion app provides medication management support that addresses the specific needs and challenges of people living with Parkinson’s

Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial of its Digital Therapy for Anxiety

●        AlmeeTM, developed by Alex Therapeutics in partnership with Vicore Pharma, is a mobile app that offers personalized treatment for anxiety based on cognitive behavioral therapy (CBT) ●        The pivotal trial demonstrated significantly reduced levels of anxiety and improved quality of life for people living with pulmonary fibrosis, a chronic and fatal disease   Stockholm, January 4, 2024 – Alex Therapeutics and Vicore Pharma today announced positive results of the COMPANION study, investigating the efficacy of Almee, a 9-week digital cognitive behavioral therapy (CBT)

Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety

· The Digital Therapeutic (DTx) was developed by DTx leader Alex Therapeutics using the proprietary “Alex DTx Platform”[1] in partnership with Vicore Pharma · In the study patients with Idiopathic Pulmonary Fibrosis (IPF) and anxiety were given the DTx · Safety, functionality, and user experience were all studied and found positive · Average reduction in anxiety, GAD-7*, was 4.2 points · Pivotal phase of study is to be launched in Q4, 2022   Stockholm, 13th October, 2022 - Alex Therapeutics is a DTx Software-as-a-medical-device (SaMD) manufacturer developing and licensing

Clinical study investigating Alex Therapeutics’ and Vicore’s standalone digital therapy (DTx) treating anxiety in patients with idiopathic pulmonary fibrosis (IPF) has launched in the US

· The DTx, Almee[TM], under clinical study was built on Alex Therapeutics proprietary “Alex DTx Platform”[1] · First clinical study with a digital therapy (DTx) in patients with IPF to address the psychological symptom burden in this disease · First patient enrolled in US pilot phase leading up to US pivotal phase of the study · The DTx is developed by Alex Therapeutics in collaboration with Vicore Pharma (”Vicore). Vicore is responsible for the clinical validation and commercialisation of the DTx Stockholm, April 21, 2022 - Alex Therapeutics, a Digital Therpautics (DTx) Software

Alex Therapeutics raises €3.5M in oversubscribed financing round from top tier VC investors to advance expansion in Europe and the US.

Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics today announces it has secured a €3.5M funding round, led by European life science venture fund Hadean Ventures and joined by Scale Capital and Bonit Capital.Alex Therapeutics aspires to become the global go-to partner for pharma, and other life-science companies seeking to develop and launch DTx solutions. These digital health products are validated in clinical trials and prescribed by a doctor, similar to traditional therapeutics. This funding round will be used to accelerate Alex's growth in Europe and the US and to

Pfizer and Alex Therapeutics announce a Strategic Commercial Partnership to provide evidence-based Digital Therapeutics to patients, starting in Germany.

The Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics and world leading pharmaceutical company Pfizer have joined forces to provide evidence based, clinically validated and personalized digital therapies to patients. Together, the companies cover a broad range of expertise in the fields of medicine, marketing, clinical validation, AI, software development and psychology. The partnership will initially focus on Germany, one of the world's largest unified healthcare markets. “In our efforts to give patients access to new, innovative forms of therapy, it is our aim to

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media